Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Registry study of zimberelimab regimens in advanced gastrointestinal tumors
ChiCTR2200060180Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab in gastrointestinal neoplasia, sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Objective response rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
zimberelimab
03
Conditions
gastrointestinal neoplasia
Beyond the preview
Go deeper on ChiCTR2200060180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060180.